Investors
Key investment highlights in AlzeCure
- Targeting areas of huge unmet medical needs
- Strong team with extensive experience and track record
- Platforms with first-in-class properties and potential game-changers
- Parallel investments in several candidates and potent follow-up programs
- Multi-billion dollar market opportunity areas
- Phase II company
Press releases
-
Positive results from the Phase Ib clinical study of NeuroRestore ACD856, under development for Alzheimer’s
June 16, 2026
-
The subscription period in AlzeCure Pharma’s Rights Issue begins today
June 16, 2026
-
AlzeCure Pharma enters into a collaboration and out-licensing agreement with Lilly for Alzheimer’s project
June 9, 2026